Business
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2022 supports advancing robust pipeline into 2026, through multiple
About this update from Lyell Immunopharma, Inc.
[{"type":"text","content":"Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2022 supports advancing robust pipeline into 2026, through multiple clinical milestonesPhase 1 clinical trials initiated for two wholly-owned product candidates for the treatment of solid tumorsNonclinical data highlighting CAR T cell and TIL product candidates designed for differentiated potency and durability presented at multiple scientific conferences SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022. “Lyell continued to gain momentum in 2022 with the initiation of two Phase 1 clinical trials for our wholly-owned CAR T cell and TIL product candidates, and we head into 2023 with a goal of accelerating this momentum to generate clinical data from these trials as rapidly as possible,” said Lynn Seely, M.D., Lyell’s President and CEO. “We continued to invest in our innovative reprogramming technologies and recently announced two product candidates in preclinical development that incorporate new stackable technologies designed to further enhance T-cell potency and cytotoxicity to defeat solid tumors. Our strong financial position with cash runway into 2026 positions us to demonstrate the value of our two lead clinical programs that target solid tumors with large unmet needs while continuing to invest in and develop our innovative pipeline.” Fourth Quarter Updates and Recent Business Highlights Lyell is advancing four wholly-owned product candidates: two product candidates, LYL797 and LYL845, are in Phase 1 clinical development and two additional product candidates, LYL119 and a TIL product candidate incorporating novel genetic and epigenetic reprogramming technologies, are in preclinical development. LYL797 – A ROR1 CAR T-cell product candidate genetically reprogrammed using c-Jun and epigenetically reprogrammed using Lyell’s proprietary Epi-RTM manufacturing protocol, designed for differentiated potency and durability Enrollment in the Phase 1 clinical trial of LYL797 is ongoing. Initial clinical data from the Phase 1 trial of LYL797 are expected in the first...